Back to top
more

Sarepta Therapeutics (SRPT)

(Real Time Quote from BATS)

$119.61 USD

119.61
254,433

-3.23 (-2.63%)

Updated Jun 17, 2024 12:25 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Sarepta's (SRPT) Overdependence on Exondys 51 Hurt?

by Zacks Equity Research

Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on Exondys 51 for near-term growth is a concern.

Sarepta (SRPT) Inks New Gene Editing Research Collaboration

by Zacks Equity Research

Sarepta (SRPT) signs agreement with Genevant to develop lipid nanoparticle-based gene editing medicines targeting neuromuscular indications.

Sarepta (SRPT) Looks Good: Stock Adds 9.1% in Session

by Zacks Equity Research

Sarepta (SRPT) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Pfizer (PFE) Begins Dosing in DMD Study With Gene Therapy

by Zacks Equity Research

Pfizer (PFE) doses the first participant in the phase III CIFFREO study, evaluating its investigational gene therapy, PF-06939926, for treating boys with DMD.

Sarepta (SRPT) Down on Unsatisfactory Data for DMD Candidate

by Zacks Equity Research

Sarepta (SRPT) posts top-line results from part 1 of Study 102, evaluating a single dose of its gene therapy candidate SRP-9001 for treating DMD. Shares fall.

Sarepta (SRPT) DMD Study Shows Proof of Concept for SRP-5051

by Zacks Equity Research

Sarepta's (SRPT) ongoing phase II study data supports continued dose escalation of SRP-5051 and suggests improved efficacy on lower doses compared to Exondys 51.

Sarepta Therapeutics (SRPT) Up 8.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Selecta's (SELB) Gene Therapy Gets Orphan Drug Tag From FDA

by Zacks Equity Research

The FDA bestows an orphan drug status on Selecta's (SELB) gene therapy candidate MMA-101 for the treatment of isolated methylmalonic acidemia. The candidate already has a Rare Pediatric Disease tag.

Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Sarepta (SRPT) Q3 revenues increase year over year.

Analysts Estimate Sarepta Therapeutics (SRPT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Selecta (SELB) This Earnings Season?

by Zacks Equity Research

In absence of any marketed product, investor focus will be on Selecta's (SELB) efforts to develop its lead pipeline candidate SEL-212 during the third-quarter conference call.

Selecta's (SELB) Gene Therapy Gets Rare Pediatric Disease Tag

by Zacks Equity Research

The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.

Roche Buys NLRP3 Inflammasome Inhibitors Developer Inflazome

by Zacks Equity Research

Roche (RHHBY) buys Inflazome for ???euro 380 million and gains access to pipeline of small molecule NLRP3 inhibitors.

Why Is Sarepta Therapeutics (SRPT) Down 11.5% Since Last Earnings Report?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sarepta's Casimersen NDA Gets Priority Review From FDA

by Zacks Equity Research

Sarepta (SRPT) is seeking accelerated approval for exon 45 amenable DMD candidate, casimersen. Amondys 45 is likely to be the brand name for the candidate.

Sarepta (SRPT) Q2 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Sarepta (SRPT) Q2 revenues increase year over year.

Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -6.63% and 22.25%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

What Awaits Selecta Biosciences (SELB) This Earnings Season?

by Zacks Equity Research

In the absence of any marketed drugs, investor focus is likely to be on Selecta Biosciences' (SELB) lead pipeline candidate, SEL-212 on the second-quarter conference call.

Kinjel Shah headshot

Drug/Biotech Stock Q2 Earnings on Aug 5: REGN, MRNA & More

by Kinjel Shah

Let us take a look at five drug/biotech companies, REGN, MRNA, SRPT, ACAD and HZNP, which are gearing up for their earnings release.

Will Sarepta Therapeutics (SRPT) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Sarepta Completes Rolling NDA Submission for New DMD Therapy

by Zacks Equity Research

Sarepta (SRPT) is seeking accelerated approval for its third exon-skipping therapy, casimersen, for DMD patients.

Sarepta Inks Agreement With Codiak to Develop Gene Therapies

by Zacks Equity Research

Sarepta (SRPT) and Codiak BioSciences sign agreement to develop potential gene therapies targeting neuromuscular indications using Codiak's engineered exosomes.

Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE